CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Precigen
PGEN
$1.36B
| $9.32K | ﹤0.01% |
6,561
+3,212
| +96% | +$4.56K |
|
352
ARS Pharmaceuticals
SPRY
$1.06B
| $9.27K | ﹤0.01% |
2,453
+1,211
| +98% | +$4.58K |
|
|
AMRN
353
Amarin Corp
AMRN
$311M
| $9.08K | ﹤0.01% |
494
+242
| +96% | +$4.45K |
|
354
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $9.07K | ﹤0.01% |
2,426
+1,193
| +97% | +$4.46K |
|
|
CNTA
355
Centessa Pharmaceuticals
CNTA
$2.12B
| $8.78K | ﹤0.01% |
1,357
+666
| +96% | +$4.31K |
|
356
Arbutus Biopharma
ABUS
$769M
| $8.72K | ﹤0.01% |
4,296
+2,119
| +97% | +$4.3K |
|
357
Arcutis Biotherapeutics
ARQT
$1.94B
| $8.44K | ﹤0.01% |
1,590
+785
| +98% | +$4.17K |
|
|
BLUE
358
DELISTED
bluebird bio
BLUE
| $8.35K | ﹤0.01% |
137
+67
| +96% | +$4.08K |
|
359
MaxCyte
MXCT
$145M
| $8.31K | ﹤0.01% |
2,663
+1,312
| +97% | +$4.09K |
|
360
Terns Pharmaceuticals
TERN
$618M
| $7.85K | ﹤0.01% |
1,560
+817
| +110% | +$4.11K |
|
361
Seres Therapeutics
MCRB
$165M
| $7.82K | ﹤0.01% |
164
+80
| +95% | +$3.81K |
|
362
Humacyte
HUMA
$231M
| $7.8K | ﹤0.01% |
2,661
+1,306
| +96% | +$3.83K |
|
363
PMV Pharmaceuticals
PMVP
$76.3M
| $7.68K | ﹤0.01% |
1,251
+651
| +109% | +$4K |
|
|
ME
364
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $7.65K | ﹤0.01% |
391
+199
| +104% | +$3.89K |
|
365
Erasca
ERAS
$420M
| $7.63K | ﹤0.01% |
3,875
+1,899
| +96% | +$3.74K |
|
366
MeiraGTx Holdings
MGTX
$621M
| $7.47K | ﹤0.01% |
1,522
+743
| +95% | +$3.65K |
|
367
MacroGenics
MGNX
$123M
| $7.44K | ﹤0.01% |
1,597
+786
| +97% | +$3.66K |
|
368
Fulcrum Therapeutics
FULC
$372M
| $7.08K | ﹤0.01% |
1,594
+784
| +97% | +$3.48K |
|
|
IGMS
369
DELISTED
IGM Biosciences
IGMS
| $6.99K | ﹤0.01% |
837
+450
| +116% | +$3.76K |
|
370
Lexicon Pharmaceuticals
LXRX
$389M
| $6.85K | ﹤0.01% |
6,286
+3,801
| +153% | +$4.14K |
|
371
Xeris Biopharma Holdings
XERS
$1.27B
| $6.59K | ﹤0.01% |
3,541
+1,742
| +97% | +$3.24K |
|
372
Phibro Animal Health
PAHC
$1.58B
| $6.56K | ﹤0.01% |
514
+247
| +93% | +$3.15K |
|
373
Generation Bio
GBIO
$38.9M
| $6.42K | ﹤0.01% |
170
+84
| +98% | +$3.17K |
|
374
Atea Pharmaceuticals
AVIR
$264M
| $6.42K | ﹤0.01% |
2,139
+1,046
| +96% | +$3.14K |
|
375
Ocular Therapeutix
OCUL
$2.21B
| $6.41K | ﹤0.01% |
2,040
+1,024
| +101% | +$3.22K |
|